We searched for studies that used estrogen alone; estrogen in combination with progestogens; synthetic steroids, (such as tibolone); selective estrogen receptor modulators (SERMs, that affect how ...

SERMs and SERDS are some of the latest weapons in the fight against breast cancer. Find out how they can treat -- and in some cases prevent -- the disease.

SERMs form an oestrogen-like class of drug which is able to bind to oestrogen receptors of one organ system while remaining neutral to others. The SERM used in South Africa to prevent osteoporosis is ...

From July 2019 through March 2023, Hall brought in an estimated $3.8 million in income, according to prosecutors, “at least in part from the sale of unapproved drugs” including raloxifene ...

Selective estrogen receptor modulators (SERMs): These drugs include tamoxifen and raloxifene. They may lower the risk of breast cancer in people who are at very high risk.

Examples of SERMs approved by the FDA are tamoxifen (Nolvadex), raloxifene (Evista), and toremifene (Fareston). Tamoxifen has been used for more than 40 years to treat patients with HR-positive ...

The mental health of the placebo group improved more over 12 months than the raloxifene group. The return of pain post-surgery occurred earlier for women taking the SERM treatment, and the study ...

The findings, from nearly 50,000 individuals in a nationwide Taiwanese database from 2009 until 2018, suggest that alendronate / risedronate, denosumab, and zoledronic acid all result in a ...

SERMs block estrogen receptors in cancer cells so the hormone can't spur tumor growth, while letting estrogen act normally in other tissues such as bone and liver tissue; examples of SERMs include ...

Two of the most common SERMs are tamoxifen (Nolvadex, Soltamox) and raloxifene (Evista). There are several others as well, including lasofoxifene, bazedoxifene, and clomiphene citrate.

Among SERMs, raloxifene was the most widely prescribed drug in both datasets, but bazedoxifene users were also identified and included in SIDIAP.